We are live on ! Find out more
Commodore Capital

Commodore Capital Portfolio holdings

AUM $1.68B Turnover 31.71%
1-Year Est. Return 375.52%
This Fund
S&P 500
This Quarter Est. Return
+36.31%
1 Year Est. Return
+375.52%
3 Year Est. Return
+2,120.72%
5 Year Est. Return
+8,694.03%
10 Year Est. Return
–
AUM
$890M
AUM Growth
+$233M
Cap. Flow
+$63.4M
Cap. Flow %
7.12%
Top 10 Hldgs %
74.13%
Holding
34
New
2
Increased
15
Reduced
2
Closed
8
Avg Time Held
1 year
Top 10 Avg Time Held
0.9 years
Top 20 Avg Time Held
0.9 years

Top Buys

Rank Stock Value
1
AKRO icon
Akero Therapeutics
AKRO
+$40.6M
2
PCVX icon
Vaxcyte
PCVX
+$38.6M
3
VERA icon
Vera Therapeutics
VERA
+$23.7M
4
MRUS icon
Merus
MRUS
+$23M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$15.9M

Top Sells

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$47.4M
2
AMAM
Ambrx Biopharma Inc
AMAM
+$20.5M
3
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$13.6M
4
IMVT icon
Immunovant
IMVT
+$10.1M
5
RNAM
Avidity Biosciences
RNAM
+$9.07M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MRUS icon
1
DELISTED
Merus
MRUS
$105M 11.84%
4,000,000
+1,050,000
+36% +$23M
2021 Q3
7 quarters
VERA icon
2
Vera Therapeutics
VERA
$2.02B
$87.5M 9.83%
5,450,000
+2,625,971
+93% +$23.7M
2023 Q1
1 quarter
AKRO icon
3
DELISTED
Akero Therapeutics
AKRO
$78.2M 8.79%
1,675,000
+885,000
+112% +$40.6M
2022 Q3
3 quarters
XENE icon
4
Xenon Pharmaceuticals
XENE
$3.42B
$71M 7.98%
1,845,000
– –
2020 Q4
10 quarters
COGT icon
5
Cogent Biosciences
COGT
$5.42B
$65.9M 7.41%
5,566,026
+793,605
+17% +$9.1M
2020 Q4
10 quarters
VRDN icon
6
Viridian Therapeutics
VRDN
$2.53B
$52.3M 5.88%
2,200,000
+10,341
+0.5% +$265K
2021 Q1
9 quarters
AMAM
7
DELISTED
Ambrx Biopharma Inc
AMAM
$52.3M 5.87%
3,175,000
-1,628,447
-34% -$20.5M
2023 Q1
1 quarter
PCVX icon
8
Vaxcyte
PCVX
$9.5B
$50.7M 5.7%
1,015,000
+815,000
+408% +$38.6M
2022 Q4
2 quarters
NUVL icon
9
DELISTED
Nuvalent
NUVL
$48.5M 5.45%
1,150,000
+75,000
+7% +$2.84M
2022 Q4
2 quarters
ELVN icon
10
Enliven Therapeutics
ELVN
$3.04B
$47.9M 5.39%
2,348,272
+616,907
+36% +$12.5M
2022 Q4
2 quarters
CABA icon
11
Cabaletta Bio
CABA
$249M
$30.6M 3.44%
2,368,186
+533,186
+29% +$5.79M
2022 Q4
2 quarters
CBAY icon
12
DELISTED
Cymabay Therapeutics
CBAY
$22.2M 2.49%
2,025,000
– –
2020 Q4
10 quarters
ARWR icon
13
Arrowhead Research
ARWR
$8.2B
$21.8M 2.44%
610,000
+35,000
+6% +$1.21M
2022 Q2
4 quarters
CLDX icon
14
Celldex Therapeutics
CLDX
$2.3B
$21.4M 2.41%
631,665
+135,842
+27% +$4.58M
2022 Q1
5 quarters
SNDX icon
15
Syndax Pharmaceuticals
SNDX
$1.2B
$20.9M 2.35%
997,596
+143,712
+17% +$2.99M
2022 Q3
3 quarters
IDYA icon
16
IDEAYA Biosciences
IDYA
$3.35B
$18.2M 2.05%
+775,000
New +$15.9M
2023 Q2
0 quarters
IMVT icon
17
Immunovant
IMVT
$5.87B
$17.1M 1.92%
900,000
-540,999
-38% -$10.1M
2022 Q4
2 quarters
ADVM icon
18
DELISTED
Adverum Biotechnologies
ADVM
$15.9M 1.79%
1,000,000
+500,000
+100% +$5.26M
2023 Q1
1 quarter
CELC icon
19
Celcuity
CELC
$3.19B
$15.9M 1.78%
1,444,141
+53,369
+4% +$554K
2021 Q2
8 quarters
KURA icon
20
Kura Oncology
KURA
$855M
$14.8M 1.66%
1,400,000
+195,042
+16% +$2.31M
2022 Q1
5 quarters
ALPN icon
21
DELISTED
Alpine Immune Sciences Inc
ALPN
$13.6M 1.53%
1,325,000
– –
2022 Q3
3 quarters
DAWN icon
22
DELISTED
Day One Biopharmaceuticals
DAWN
$8.83M 0.99%
739,661
– –
2022 Q2
4 quarters
THRD icon
23
DELISTED
Third Harmonic Bio
THRD
$4.78M 0.54%
993,294
– –
2022 Q3
3 quarters
KALV icon
24
DELISTED
KalVista Pharmaceuticals
KALV
$2.81M 0.32%
312,553
– –
2021 Q1
9 quarters
SYRE icon
25
Spyre Therapeutics
SYRE
$8.44B
$1.31M 0.15%
+116,324
New +$552K
2023 Q2
0 quarters
1
2

Similar funds

Trustmark National Bank Trust Department
Trustmark National Bank Trust Department Jackson, Mississippi $1.68B AUM 19.26% 1-Year Est. Return
SH
Spear Holdings Dubai, United Arab Emirates $1.68B AUM 4.3% 1-Year Est. Return
Clearline Capital
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
Bain Capital Life Sciences Investors
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Invenomic Capital Management
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Anson Funds Management
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Commodore Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Commodore Capital held 34 positions worth $890M, up 35% from $657M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Commodore Capital deployed $63.4M of net new capital in Q2 2023, opening 2 new positions and adding to 15 existing holdings. Its largest new stake was IDEAYA Biosciences: 775,000 shares worth $18.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Ambrx Biopharma Inc, an estimated $20.5M trimmed.

  • Commodore Capital's largest Q2 2023 buy was IDEAYA Biosciences: 775,000 shares worth $18.2M.
  • Commodore Capital added most to Akero Therapeutics in Q2 2023, an estimated $40.6M increase.
  • Commodore Capital's biggest Q2 2023 reduction was Ambrx Biopharma Inc, cutting an estimated $20.5M.
  • Commodore Capital fully exited BELLUS Health Inc. in Q2 2023, selling an estimated $47.4M.
  • Commodore Capital's ten largest holdings make up 74% of its $890M portfolio in Q2 2023.
  • Commodore Capital opened 2 new positions and closed 8 in Q2 2023.
  • Commodore Capital's portfolio value rose 35% quarter-over-quarter to $890M.

Based on Commodore Capital's 13F filing for Q2 2023, filed 14 Aug 2023.